Phase 1a/b open-label study of IK-175, an oral AHR inhibitor, alone and in combination with nivolumab in patients with locally advanced or metastatic solid tumors and urothelial carcinoma

被引：0
|
作者：
McKean, Meredith
Aggen, David Henry
Lakhani, Nehal J.
Bashir, Babar
Luke, Jason J.
Hoffman-Censits, Jean H.
Alhalabi, Omar
Bowman, Isaac Alex
Guancial, Elizabeth A.
Tan, Alan
Lingaraj, Trupti
Timothy, Marissa
Kacena, Katherine
Malek, Karim S.
Santillana, Sergio
机构：
[1] Sarah Cannon Res Inst, Tennessee Oncol, PLLC, Nashville, TN USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY USA
[3] START Midwest, Grand Rapids, MI USA
[4] Thomas Jefferson Univ, Sarah Cannon Res Inst, Philadelphia, PA USA
[5] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA USA
[6] Univ Pittsburgh, Pittsburgh, PA USA
[7] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[8] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[9] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[10] Florida Canc Specialists, Sarasota, FL USA
[11] Rush Univ, Med Ctr, Chicago, IL USA
[12] Ikena Oncol, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3169
引用
收藏
页数：1
相关论文
共 50 条
  • [31] An open-label, phase 1a/b study of AB248, a CD8+selective IL-2 mutein fusion protein, alone or in combination with pembrolizumab in patients with advanced solid tumors
    Buchbinder, Elizabeth I.
    Spigel, David R.
    Albany, Costantine
    Chisamore, Michael
    Moynihan, Kelly D.
    Liu, Xiaohan
    DelNagro, Christopher
    Axt, Matt
    Pirzkall, Andrea
    CANCER RESEARCH, 2023, 83 (08)
  • [32] A PHASE 1, FIRST IN HUMAN, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY OF TST005 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS
    Chen, Lei
    Tolcher, Anthony
    Gabrail, Nashat
    Barve, Minal
    Wu, Xiaohua
    Zhang, Jian
    Shi, Michael
    Qi, Chuan
    Yu, Steven
    Yao, Jenny
    Wang, Jianming
    Cavanaugh, Christopher
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A802 - A802
  • [33] A phase 1, open-label, drug–drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors
    Mingxiang Liao
    Krzysztof G. Jeziorski
    Monika Tomaszewska-Kiecana
    István Láng
    Marek Jasiówka
    Viera Skarbová
    Piotr Centkowski
    Rodryg Ramlau
    Maria Górnaś
    John Lee
    Sarah Edwards
    Jenn Habeck
    Eileen Nash
    Nikolay Grechko
    Jim J. Xiao
    Cancer Chemotherapy and Pharmacology, 2021, 88 : 887 - 897
  • [34] An open-label, global, first-in-human study of SKB264 in patients with locally advanced or metastatic solid tumors
    Rodon, J.
    Li, J.
    Xue, J.
    Diao, Y.
    Xu, Y.
    Liu, G.
    Rao, C.
    Fan, B.
    Cheng, Y.
    Wang, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S585 - S585
  • [35] Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2 study
    Finn, Richard S.
    Ryoo, Baek-Yeol
    Hsu, Chih-Hung
    Li, Daneng
    Burgoyne, Adam M.
    Cotter, Christopher
    Badhrinarayanan, Shreya
    Wang, Yulei
    Yin, Anqi
    Edubilli, Tirupathi Rao
    Mahrus, Sami
    Secrest, Matthew H.
    Shemesh, Colby S.
    Yu, Nancy
    Hack, Stephen P.
    Cha, Edward
    Gane, Ed
    LANCET ONCOLOGY, 2025, 26 (02): : 214 - 226
  • [36] Cardiovascular safety of pimitespib in patients with advanced solid tumors: An open-label, nonrandomized, phase 1 study
    Naoki, Katsuhiko
    Igawa, Satoshi
    Uojima, Haruki
    Tsumura, Hideyasu
    Sengoku, Norihiko
    Karayama, Masato
    Shimomura, Akihiko
    Ohtake, Tohru
    Shio, Yutaka
    Hosokawa, Ayumu
    Komatsu, Yoshito
    Kumagai, Yuji
    CANCER, 2024, 130 (21) : 3745 - 3756
  • [37] A first-in-human, open-label, multi-center phase 1 study of TST003, a GREM 1 inhibitor, in subjects with locally advanced or metastatic solid tumors
    Rivera, Ismael Rodriguez
    Shen, Lin
    Kummar, Shivaani
    Barve, Minal
    Germa, Caroline
    Qi, Chuan
    Chen, Lei
    Milata, Jenny
    Yao, Jenny
    Shen, Li
    Zhu, Xuelian
    CANCER RESEARCH, 2024, 84 (06)
  • [38] Phase II study of sitravatinib in combination with nivolumab in patients with advanced or metastatic urothelial carcinoma (UC) after checkpoint inhibitor therapy (CIT).
    Doshi, Gurjyot K.
    Vogelzang, Nicholas J.
    Richards, Donald A.
    Chong, Daniel
    Shaffer, David R.
    Nordquist, Luke T.
    Picus, Joel
    Alvarez, Delia
    Der-Torossian, Hirak
    Christensen, James
    Yorio, Jeffrey Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [39] Phase 2 study of HDAC inhibitor tucidinostat in combination with anti-PD-1 antibody in patients with locally advanced or metastatic urothelial carcinoma
    Liu, Zhuowei
    Jiang, Lijuan
    Li, Xiangdong
    Ye, Yunlin
    Wu, Zhiming
    An, Xin
    Shi, Yanxia
    Yao, Kai
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [40] An open-label, multicenter, phase I study of ATG-022 in patients with advanced/metastatic solid tumors (CLINCH).
    Bishnoi, Sarwan
    Cao, Dan
    Mendis, Shehara Ramyalini
    Coward, Jim
    Zhao, Jun
    Xie, Hui
    Zheng, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345